Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?
09:41am, Wednesday, 16'th Jul 2025
VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
04:05pm, Tuesday, 08'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance Prostate and Bladder Cancer Resea
Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and
Veracyte to Participate in Upcoming Investor Conferences
05:00pm, Tuesday, 20'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Bla
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
09:40am, Monday, 19'th May 2025
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
02:30pm, Friday, 09'th May 2025
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
What Makes Veracyte (VCYT) a New Buy Stock
01:05pm, Thursday, 08'th May 2025
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
12:49am, Thursday, 08'th May 2025
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Finan
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
08:00pm, Wednesday, 07'th May 2025
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
07:00am, Friday, 25'th Apr 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
10:15am, Thursday, 17'th Apr 2025
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
10:50am, Tuesday, 15'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
